Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

Company Reiterates 2008 Earnings Guidance and Introduces Q1 2008 Guidance

FRAZER, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported 2007 sales of $1.727 billion, compared to sales of $1.720 billion for 2006, exceeding the company's previously issued guidance. Basic loss per common share for the full year 2007 was $2.88. Excluding the previously announced settlement reserve, amortization expense and certain other items, basic adjusted income per common share for the full year was $4.64, which compares to $5.22 for 2006 and exceeds the high end of the company's earnings guidance range of $4.45 to $4.55.

2007 central nervous system (CNS) franchise sales increased 16 percent to $909.4 million compared to 2006 and the pain franchise reported strong sales of $512.6 million, a decrease of only 22 percent despite a full year of generic competition to ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. Sales of other products increased 15 percent to $305.3 million.

"We delivered strong performance across all aspects of our business in 2007. We launched AMRIX, filed three NDAs, introduced three new Phase 1 programs, and delivered greater sales and earnings than expected," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We believe that 2008 will mark the beginning of a new phase of growth for the company with a full year of AMRIX sales, the potential for approval of TREANDA and expanded indications for FENTORA, and continued progress on the clinical development plan for NUVIGIL. In fact, the NUVIGIL program is already off to a great start with promising results from our first Phase 2 study in the treatment of schizophrenia."

The company is reiterating its guidance for 2008 total sales of $1.80 - $1.85 billion, adjusted net income of $344 - $351 million and its basic adjusted income per common share guidance of $5.10 - $5.20.

Cephalon is introducing first quarter 2008 sales guidance of $435 - $445 mil
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Follow us on LinkedIn ... the world over, due to its use of ... marketplace is expected to come from increasing adoption ... Several sub-Saharan countries in the African continent, which ... genetically engineered crop production strategies. Rising focus on ...
(Date:9/23/2014)... Sept. 23, 2014 News Facts ... India devoted to genome-based research for human health ... is taking a bite out of oral cancer with ... in India with the help of ... DataDirect Networks (DDN). , To fuel its cutting-edge cancer ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart ... in the recent ‘Hype Cycle for Life Sciences 2014 ... details key insights pertaining to the benefits in the ... Michael Shanler and Stephen Davies, “The use of these ... with scientific stakeholders, and support collaboration and innovation strategies ...
(Date:9/23/2014)... Texas Fertility Center (TFC) announces the ... expanding a Central Texas footprint that includes Round Rock, ... office for the region’s most established practice will provide ... Austin, Buda, Kyle and San Marcos communities. , ... directly to individuals and couples living in and around ...
Breaking Biology Technology:Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3
... MMPSense(TM) 750 FAST is Presented at AACR 100th Annual ... leader in fluorescence in vivo imaging from ... new FAST ("Fluorescent Activatible Sensor Technology") imaging ... and drug response in vivo . Newly ...
... (Nasdaq: MYL ) today announced that Matrix ... a 71.2% controlling interest, has been selected by the ... the primary supplier of five antiretroviral (ARV) drugs used ... selected as the primary supplier of seven ARVs used ...
... for the Company Building on Milestones with Recent ... DXL625 monoclonal antibodies appear to ... to attach and deplete NHL in late stage ... Biotechnology Inc. (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com ...
Cached Biology Technology:VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 2VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 3VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 4Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 2Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 3AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:9/22/2014)... the country selected by the National Institutes of ... a $2 million grant designed to expose ... graduate trainees to career opportunities that go beyond ... , The award funds development of the Rutgers ... It includes courses, seminars, shadowing, mentoring and networking ...
(Date:9/22/2014)... manufacturing (AM), or 3D printing, has rapidly advanced ... components strong enough for structural applications. However, developing ... well as quality standards to test the manufactured ... Engineers at the University of Pittsburgh,s Swanson School ... and simulation (M&S) technology and new qualification standards ...
(Date:9/22/2014)... you,re overweight, you may be at greater risk ... disease and cancer, according to a new study ... psychological stress can trigger biological responses similar to ... While normal inflammation is an important part of ... to chronic and life-threatening diseases. , In ...
Breaking Biology News(10 mins):Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3Obesity and stress pack a double hit for health 2
... An Australian bird has been found to produce smaller, ... of other helper birds that provide child-care assistance. ... and breed more often than females without helpers. ... today made the front cover of Science. In ...
... mice, carbon dioxide often means danger - too many ... hungry predator exhaling nearby. Mice have a way of ... shows that a special set of olfactory neurons is ... predicted increases in atmospheric carbon dioxide may affect animal ...
... Berkeley -- Delaying having kids to help raise the ... you want to reproduce, but many African starlings have ... of their savanna habitats, according to a new study ... It appears in the Aug. 21 issue of the ...
Cached Biology News:Mother's little helpers 2Mice use specialized neurons to detect carbon dioxide in the air 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 2Savanna habitat drives birds, and perhaps others, to cooperative breeding 3Savanna habitat drives birds, and perhaps others, to cooperative breeding 4
Anti-human C5a/C5a des-Arg (neo-epitode), Clone 2952, Monoclonal Antibody...
...
Reacts with the 80 kDa fragment of the M-chain of human merosin....
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: